证券代码：603990 证券简称：麦迪科技 公告编号：2023-077 苏州麦迪斯顿医疗科技股份有限公司 关于使用部分闲置募集资金进行现金管理赎回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 苏州麦迪斯顿医疗科技股份有限公司（以下简称"公司"）于 2023 年 4 月 27 日召开第四届董事会第六次会议、第四届监事会第三次会议，审议通过了《关于 使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金 投资项目进度和募集资金安全的前提下，对暂时闲置的部分募集资金不超过人民 币 3 亿元（包含本数）进行现金管理，余额在上述额度内，资金可以滚动使用， 用于购买单笔期限最长不超过 12 个月（含 12 个月）的结构性存款、大额存单等 安全性高的保本型产品，不得用于证券投资。公司独立董事、监事会及保荐机构 已分别对前述事项发表了同意的意见。具体内容详见公司于 2023 年 4 月 29 日披 露的《关于使用部分闲置募集资金进行现金管理的公告》(公告编号：2023-043)。 一、 公司募集资金现金管理到期赎回情 ...

一、 募集资金基本情况 证券代码：603990 证券简称：麦迪科技 公告编号：2023-076 苏州麦迪斯顿医疗科技股份有限公司 关于募集资金专户销户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特此公告。 经中国证券监督管理委员会《关于核准苏州麦迪斯顿医疗科技股份有限公司 非公开发行股票的批复》（证监许可[2022]2863号）核准，苏州麦迪斯顿医疗科 技股份有限公司（以下简称"公司"）实际非公开发行人民币A股股票21,440,134 股（每股面值1.00元人民币），发行价格为每股人民币11.14元。本次非公开发 行募集资金总额为238,843,092.76元，扣除发行费用人民币8,207,547.17元（不 含税）后，募集资金净额为230,635,545.59元。中汇会计师事务所(特殊普通合 伙)已于2022年12月26日对本次非公开发行的资金到位情况进行了审验，并出具 了《验资报告》（中汇会验[2022]8006号），公司对募集资金采取了专户存储制 度。 苏州麦迪斯顿医疗科技股份有限公司董事会 二、 募集资金账 ...

证券代码：603990 证券简称：麦迪科技 公告编号：2023-078 苏州麦迪斯顿医疗科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 因减持计划时间届满，汪建华先生本次减持计划已执行完毕。 大股东及董监高持股的基本情况 截至本公告披露日，苏州麦迪斯顿医疗科技股份有限公司（以下简称 "公司"）股东汪建华先生持有公司股份 3,790,000 股，占公司股本总数的 1.2374%。 减持计划的实施结果情况 上述减持主体无一致行动人。 公司于 2023 年 1 月 14 日披露了《苏州麦迪斯顿医疗科技股份有限公 司股东减持股份计划公告》（公告编号：2023-011），汪建华先生计划于 2023 年 2 月 13 日至 2023 年 8 月 12 日期间通过竞价交易方式，2023 年 1 月 19 日至 2023 年 7 月 18 日期间通过大宗交易方式择机减持公司股份合计不超 过 968,375 股，即不超过其持有公司股份总数的 25%，不超过公司总股本 的 0.41 ...

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 33,560,503.99 in 2022, with the parent company reporting a net profit of RMB 62,833,473.17[6]. - In 2022, the company's operating revenue was approximately ¥305.51 million, a decrease of 13.66% compared to ¥353.85 million in 2021[26]. - The net profit attributable to shareholders was approximately ¥33.56 million, down 20.01% from ¥41.95 million in 2021[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥24.79 million, a decrease of 25.00% from ¥33.06 million in 2021[26]. - The total profit amounted to CNY 4,355.59 million, down 15.16% year-on-year[56]. - The company reported a significant decrease in trading financial assets, down CNY 233,073,253.21, primarily due to the redemption of bank wealth management products[34]. - The company achieved a revenue of 48.69 million yuan and a net profit of 15.01 million yuan in 2022, with total assets amounting to 75.99 million yuan and net assets of 58.76 million yuan[44]. Investment and Capital Plans - The company plans to invest approximately RMB 1.862 billion in a new 9GW high-efficiency monocrystalline battery intelligent manufacturing plant in Mianyang, which will serve as a major manufacturing base for its photovoltaic industry[6]. - The proposed capital reserve conversion plan involves a distribution of 3 new shares for every 10 shares held, increasing the total share capital from 235,841,478 to 306,282,731 shares[7]. - The planned investment in the new manufacturing facility is expected to exceed 30% of the company's most recent audited total assets within the next twelve months[6]. - The company will not distribute cash dividends for the 2022 fiscal year to ensure the smooth implementation of its photovoltaic projects[6]. Operational Challenges and Risks - The company faced project implementation delays due to public health requirements, impacting revenue and project acceptance[26]. - The company has outlined potential risks associated with its operations in the management discussion and analysis section of the report[10]. - The company is focusing on expanding its market presence and enhancing its product offerings in response to industry demand fluctuations[26]. Research and Development - The company completed a significant R&D project with an investment of 260.38 CNY million aimed at building an integrated clinical data center for critical care[80]. - The company has completed the development of a non-contact vital signs monitoring system using IoT sensor technology, aimed at enhancing patient monitoring in critical care settings[82]. - The company is focused on developing comprehensive data management solutions, including the Cardiac Arrest Data Management Software V1.0, to support clinical research and improve patient care[90]. - The company is advancing its digital and intelligent medical development strategy, aligning with national AI development plans[84]. Market Position and Strategy - The company has established a leading market position in the clinical informationization field, with over 2,100 medical institutions using its DoCare series products across 32 provinces in China[49]. - The company aims to leverage data analysis and mining to achieve intelligent medical decision support, enhancing overall hospital management and research capabilities[44]. - The company is actively pursuing strategic partnerships with upstream silicon wafer manufacturers and aims to establish a joint venture for energy storage solutions[122]. Governance and Compliance - The company has established a comprehensive internal control management system in compliance with relevant laws and regulations, and has engaged external consultants for implementation during the reporting period[178]. - The company maintained effective communication with investors through various channels, including a dedicated investor hotline and email[130]. - The company has a structured approach to managing subsidiaries, ensuring compliance with internal control systems and enhancing operational effectiveness[179]. Environmental and Social Responsibility - The company donated RMB 500,000 to the Red Cross Society in Mianyang, Sichuan, for public health prevention efforts in October 2022[188]. - The company encourages employees to adopt low-carbon lifestyles and has implemented measures to reduce carbon emissions, such as promoting video conferencing and electronic document management[186]. - The company does not belong to the key pollutant discharge units and actively complies with environmental policies to mitigate pollution[183]. Future Outlook - The company aims to achieve an average net profit of no less than RMB 30 million per year for 2022, 2023, and 2024, totaling at least RMB 90 million[191]. - The company plans to strengthen technical innovation and application of new technologies, particularly in emergency medical services and public health collaboration[118]. - The management has provided guidance for the next fiscal year, projecting a revenue growth target of approximately 10%[143].

Financial Performance - The company's operating revenue for Q1 2023 was ¥70,774,875.02, representing a year-on-year increase of 24.24%[5] - The net profit attributable to shareholders was -¥10,774,232.85, a decrease of 215.17% compared to the same period last year[5] - The basic earnings per share for the period was -¥0.05, reflecting a decline of 225.00% year-on-year[6] - Total operating revenue for Q1 2023 reached ¥70,774,875.02, a 24.3% increase from ¥56,966,471.66 in Q1 2022[18] - Net profit for Q1 2023 was a loss of ¥10,167,542.40, compared to a profit of ¥10,448,933.69 in Q1 2022, marking a significant decline[19] - Total comprehensive income for Q1 2023 was a loss of ¥10,167,542.40, contrasting with a comprehensive income of ¥10,448,933.69 in Q1 2022[20] Cash Flow and Liquidity - The cash flow from operating activities was -¥17,869,040.15, indicating a significant cash outflow[5] - Cash flow from operating activities showed a net outflow of ¥17,869,040.15 in Q1 2023, an improvement from a net outflow of ¥32,355,795.24 in Q1 2022[21] - Cash and cash equivalents at the end of Q1 2023 totaled ¥476,980,677.32, down from ¥644,093,513.66 at the end of Q1 2022[23] - The company reported a decrease in cash and cash equivalents by 45.89% due to operational expenditures during the reporting period[8] - Investment activities resulted in a net cash outflow of ¥386,659,252.68 in Q1 2023, compared to a net inflow of ¥325,070,667.89 in Q1 2022[23] - Financing activities generated a net cash outflow of ¥450,666.66 in Q1 2023, a decrease from a net inflow of ¥32,664,500.00 in Q1 2022[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,815,286,619.69, an increase of 11.34% from the end of the previous year[6] - As of March 31, 2023, the company's total assets amounted to RMB 1,815,286,619.69, an increase from RMB 1,630,417,953.78 at the end of 2022, reflecting a growth of approximately 11.3%[15][17] - The total current liabilities increased significantly to RMB 460,327,243.08 from RMB 263,110,017.18, marking an increase of approximately 75%[16][17] - The company’s total liabilities increased to RMB 467,274,148.14 from RMB 270,782,340.65, representing an increase of approximately 73%[17] - The company's long-term investments rose to RMB 21,815,727.11 from RMB 16,092,164.55, indicating a growth of around 35.2%[15][16] - The total equity attributable to shareholders decreased slightly to RMB 1,345,256,474.75 from RMB 1,355,986,306.78, a decrease of about 0.8%[17] Shareholder Information - The company had a total of 27,199 common shareholders at the end of the reporting period[11] - The largest shareholder, Mianyang Haoxiang Holdings Co., Ltd., holds 16.05% of the shares[11] Operational Costs and Expenses - The company experienced a 40.11% increase in main business costs due to higher revenue and a greater proportion of lower-margin products[8] - Total operating costs increased to ¥77,812,036.40 in Q1 2023, up 56.8% from ¥49,576,022.07 in Q1 2022[19] - Research and development expenses were ¥10,342,213.08 in Q1 2023, slightly up from ¥10,182,634.92 in Q1 2022[19] - The company is advancing the TOPCon battery project, which has led to a significant increase in management expenses[9] Inventory and Retained Earnings - The company’s inventory decreased to RMB 30,459,618.25 from RMB 32,447,645.65, a decline of about 6.1%[15][16] - The company’s retained earnings as of March 31, 2023, were RMB 301,640,838.13, down from RMB 312,415,070.98, a decrease of about 3.7%[17] - The company's cash and cash equivalents decreased to RMB 477,936,823.65 from RMB 883,344,513.14, representing a decline of about 46%[15][16] - The company reported a total of RMB 280,000,000.00 in trading financial assets as of March 31, 2023, compared to RMB 88,068,286.15 at the end of 2022, reflecting a significant increase of approximately 217%[15][16] Non-Current Assets - The company’s total non-current assets increased to RMB 755,847,363.35 from RMB 366,249,720.29, indicating a growth of approximately 106.5%[16][17]

调研单位名称 人员及职务 线上参与公司 2021 年度暨 2022 年第一季度网上业绩说明会 的投资者 公司董事长、董事会秘书（代行）翁康先生； 公司接待人员 及职务 公司总经理、财务总监（代管）陈剑嵩先生； 独立董事袁万凯先生。 调研主题 苏州麦迪斯顿医疗科技股份有限公司 2021 年度暨 2022 年第 一季度业绩说明会 证券代码：603990 证券简称：麦迪科技 编号：2022-001 苏州麦迪斯顿医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------|---------------------------------|--------------|-------| | 调研日期 | 2022 年 5 月 16 日 | 调研时间 | 14:00 | | | 调研地点 上交所上证路演中心 | | | | | □特定对象调研 | □分析师会议 | | | | □媒体采访 | ☑ 业绩说明会 | | | 调研形式 | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | □其他（请文字说明其他活动内容） | | | | - ...

2022 年第三季度报告 证券代码：603990 证券简称：麦迪科技 苏州麦迪斯顿医疗科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 减变动幅度 | | 年初至报告期 末比上年同期 增减变动幅度 | | --- | --- | --- | --- | --- | | | | | 年初至报告期末 | | | | | (%) | | (%) | | 营业收入 | 62,890,700.25 | -5.68 | 205,800,162.98 | -5.65 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥142,909,462.73, a decrease of 5.63% compared to ¥151,431,740.16 in the same period last year[20]. - Net profit attributable to shareholders increased by 22.66% to ¥20,156,824.26 from ¥16,432,422.45 year-on-year, driven by higher gross margins from integrated solutions and medical services[21]. - The net cash flow from operating activities decreased by 157.44% to -¥3,180,972.08, primarily due to a reduction in tax refunds received[21]. - Basic earnings per share rose by 25.00% to ¥0.10 from ¥0.08 in the previous year[20]. - The weighted average return on equity increased by 0.39 percentage points to 1.82% from 1.43% year-on-year[20]. - The total assets at the end of the reporting period were ¥1,341,562,216.25, reflecting a 2.23% increase from ¥1,312,345,034.97 at the end of the previous year[20]. - The total profit reached CNY 27.28 million, an increase of 24.29% year-on-year, while the net profit attributable to shareholders was CNY 20.16 million, up 22.66% from the previous year[43]. - The company reported a total comprehensive income of 181,640,103.35, down from the previous period[148]. Strategic Direction - The company has a comprehensive strategy for expanding its smart hospital construction and high-quality development[13]. - The company is focused on integrating information technology with clinical knowledge to achieve intelligent medical decision support[31]. - The national health policy emphasizes the development of smart healthcare and remote medical services, which aligns with the company’s strategic direction[28]. - The company aims to enhance the informationization of nursing services by leveraging technologies such as cloud computing and big data[28]. - The company plans to implement a profit distribution plan for the next three years (2022-2024) as part of its shareholder return strategy[73]. - The company is focused on strategic expansion and investment opportunities to drive future growth[76]. - The company plans to enhance its capital structure by increasing retained earnings and optimizing equity distribution strategies[150]. Market Position and Competition - The company has established a leading market position in the clinical medical information system sector, with over 2,100 medical institutions across 32 provinces in China utilizing its products[37]. - The company has accumulated a strong customer base, including over 800 top-tier hospitals, enhancing its market reputation and demonstrating significant market penetration[37]. - The medical information technology sector is projected to reach ¥84.57 billion in IT spending by 2025, indicating significant market potential[26]. - The company is positioned in the medical information technology industry, which is supported by government policies aimed at enhancing healthcare services[27]. - The company emphasizes the importance of continuous product and technology development to maintain market competitiveness, given the rapid pace of software innovation[62]. Research and Development - R&D expenses increased by 68.16% to CNY 24.06 million, reflecting the company's commitment to technology and product innovation[48]. - The company focuses on both productization and customization in its R&D, enhancing the efficiency of tailored development to meet client needs[38]. - The company has a strong emphasis on technology and R&D, collaborating with research institutions to strengthen its capabilities in artificial intelligence and other advanced technologies[39]. - The intelligent early warning system for critical patients achieved a death risk prediction performance exceeding 80%, indicating significant application value in various medical fields[44]. Governance and Compliance - The company guarantees the authenticity, accuracy, and completeness of the semi-annual report[7]. - The company has committed to maintaining transparency and compliance with legal regulations in its governance practices[74]. - The company has confirmed the election of Chen Ning as a new board member, filling a vacancy left by a departing director[75]. - The company has established a commitment to minimize and standardize related party transactions, ensuring transparency and compliance with relevant regulations[92]. Financial Management - The company reported a cash balance of RMB 492,859,399.31 as of June 30, 2022, an increase from RMB 320,129,071.07 at the beginning of the period[118]. - The total current assets amounted to RMB 980,920,234.25, slightly up from RMB 964,894,750.65 at the beginning of the period[118]. - The company's long-term equity investments decreased to RMB 17,185,112.93 from RMB 27,278,699.83[118]. - The company reported accounts receivable of RMB 244,326,804.88, slightly down from RMB 250,383,730.14[118]. - The company has established high industry barriers due to the specialized knowledge required in medical information systems, making it challenging for new entrants[40]. Risks and Challenges - The company faced risks related to large accounts receivable and potential impacts from recurring COVID-19 outbreaks affecting hospital operations and project implementations[60]. - There is a risk of operational performance volatility due to various internal and external factors that cannot be predicted or controlled[63]. - The company must accurately grasp market trends to avoid risks associated with product development delays and misalignment with market demands[62]. Shareholder Matters - The company held three shareholder meetings during the reporting period, with all proposals approved and no rejected resolutions[74]. - The company has signed a share transfer agreement with An Investment Group, which will result in a change of control, with the new controlling shareholder expected to hold 9.09% of the total share capital post-issuance[66]. - The company plans to issue A-shares to Haoxiang Holdings, which will account for 9.09% of the total share capital after issuance[98]. - The total number of shares held by the top ten shareholders is 28,434,588, accounting for 13.26% of the total share capital[109].

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 41,953,365.73 for the year 2021, with the parent company reporting a net profit of RMB 48,484,542.20[6]. - In 2021, the company's operating revenue reached approximately CNY 353.85 million, an increase of 14.86% compared to CNY 308.08 million in 2020[24]. - The net profit attributable to shareholders was CNY 41.95 million, representing an 18.37% increase from CNY 35.44 million in 2020[24]. - The total profit for the year was RMB 51.34 million, an increase of 5.69% compared to the previous year[32]. - The net profit after deducting non-recurring gains and losses increased by 28.08% to CNY 33.06 million from CNY 25.81 million in 2020[24]. - The company's cash flow from operating activities decreased by 64.13% to CNY 36.04 million, down from CNY 100.48 million in 2020[26]. - The weighted average return on net assets decreased by 1.83 percentage points to 3.83% from 5.66% in 2020[24]. - The company's total assets decreased by 13.76% to CNY 1.31 billion from CNY 1.52 billion in 2020[24]. - The company’s net assets attributable to shareholders decreased by 10.74% to CNY 1.09 billion from CNY 1.23 billion in 2020[24]. Profit Distribution and Capital Plans - The company plans to distribute no profits for 2021, with a cash dividend ratio calculated at 168.50% based on a total repurchase expenditure of RMB 70,691,870.22[6]. - The proposed capital reserve conversion plan suggests a distribution of 3 additional shares for every 10 shares held, potentially increasing the total share capital to 214,401,344 shares[7]. - The board of directors has approved the profit distribution and capital reserve conversion plan, pending shareholder meeting approval[7]. Market Expansion and Development - The company reported a significant increase in market expansion efforts, particularly in hospital information technology, due to government investments[25]. - The company plans to continue developing new medical divisions and enhancing its service offerings in response to market demands[26]. - The company aims to enhance its CIS business by developing three major segments: "Operating Room," "ICU," and "Emergency Rescue," focusing on product advantages and market barriers[112]. - The company is actively expanding its market presence through the acquisition of Mary Hospital, which is expected to strengthen its operational capabilities[95]. Research and Development - The company has filed for and obtained 11 patents during the reporting period, including 7 invention patents[35]. - The company is developing an AI-based cardiovascular patient management platform, with an investment of RMB 674.21 million[83]. - Total R&D expenses amounted to RMB 71,265,936.52, representing 20.14% of total revenue[80]. - The company increased its R&D investment by 11.56% compared to the previous year, with expenses reaching RMB 48,004,978.09[79]. - The number of R&D personnel is 281, accounting for 39.25% of the total workforce[81]. Operational Challenges and Risks - The company has outlined potential risks in its operations, which are detailed in the management discussion section of the report[9]. - The company emphasizes the importance of investment risk awareness due to uncertainties in future plans and projections[8]. - The company faces risks related to the COVID-19 pandemic, which could delay project implementations and affect revenue recognition[116]. - Seasonal fluctuations in business operations are expected, with project completion and payment concentrated in the second half of the year, potentially leading to lower net profits in the first two quarters[117]. Governance and Compliance - The company has established a robust internal control system and revised various management regulations to enhance risk management capabilities[123]. - The audit report issued by Zhonghui Certified Public Accountants confirms the accuracy and completeness of the financial statements[5]. - The company has not reported any significant deficiencies in internal control during the reporting period[159]. - The company has disclosed 4 regular reports and 115 temporary announcements during the reporting period, ensuring transparent communication with investors[123]. Employee and Management Structure - The company reported a total of 716 employees, with 414 in the parent company and 302 in major subsidiaries[147]. - The employee composition includes 281 technical staff, 182 production personnel, and 96 sales personnel[147]. - The management team has extensive experience in various sectors, including finance and healthcare, which supports strategic decision-making[133]. - The company emphasizes talent development and offers targeted training programs for employees[150]. Environmental and Social Responsibility - The company does not belong to the key pollutant discharge units and actively fulfills its environmental responsibilities, adhering to all environmental policies[162]. - The company promotes energy conservation and resource efficiency through initiatives like double-sided printing and electronic documentation, contributing to environmental protection[164]. - The company emphasizes social responsibility by enhancing employee welfare and ensuring health and safety during the pandemic[166]. Financial Management and Investments - The company has made significant investments in R&D, focusing on AI-driven medical solutions, which are expected to drive future growth[91]. - The company has established partnerships with local health authorities, such as the Suzhou Health Commission, to enhance its software solutions in the healthcare sector[89]. - The company has initiated an employee stock ownership plan[138]. - The company plans to invest in establishing the招商麦迪医疗基金[139].

2022 年第一季度报告 证券代码：603990 证券简称：麦迪科技 苏州麦迪斯顿医疗科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增减变动 | | | --- | --- | --- | --- | | | | 幅度(%) | | | 营业收入 | 56,966,471.66 | | 20.97 | | 归属于上市公司股东的净利润 | 9,355,000.81 | | 39.31 | | 归属于上市公司股东的扣除非经常 | 8,821,487.2 ...